Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
Puma Biotechnology to Join Russell 3000 Index
09:00am, Tuesday, 28'th May 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
01:01pm, Friday, 24'th May 2024
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
05:15pm, Thursday, 23'rd May 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
12:36pm, Friday, 03'rd May 2024
Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript
10:11pm, Thursday, 02'nd May 2024
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Ex
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
07:06pm, Thursday, 02'nd May 2024
Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.09 per share a year ago.
Puma Biotechnology Reports First Quarter Financial Results
04:05pm, Thursday, 02'nd May 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will report its financial results for 1Q-2024 after the close and host a conference call at 1:30 p.m. PT on May 2.
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
12:40pm, Friday, 26'th Apr 2024
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
11:06am, Thursday, 25'th Apr 2024
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
07:13am, Friday, 19'th Apr 2024
If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
04:15pm, Thursday, 18'th Apr 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
07:06pm, Thursday, 11'th Apr 2024
Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Wednesday, 03'rd Apr 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
10:26am, Friday, 22'nd Mar 2024
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
